Live
FierceBiotechAdvances and Opportunities in Dual Chamber InjectablesFierceBiotechAchieving Effective Manufacturing Scaleup for Clinical and Commercial SuccessFierceBiotechUtilizing AI to Facilitate Combination Product DevelopmentFierceBiotechEnsuring Sustainability Throughout Drug and Device DevelopmentFierceBiotechUsing Digital Technologies to Enhance Patient Experience and Better Manage Supply ChainEndpoints NewsCDER chief Høeg expected to leave FDA, according to sourceClinical OMICsPPG-Derived Digital Biomarker Developed for Peripheral Artery Disease DetectionCharles RiverCharles River Laboratories stock (US1591881009): recent earnings and outlook under the microscope - AD HOC NEWSClinical OMICsAntibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine CancerClinical OMICsExchange Marketplace Launched to Help Stalled Cell and Gene TherapiesClinical OMICsSingle Psilocybin Dose Relieves Depression for Over Three MonthsFierceBiotechAfter Makary departure, CDER chief Tracy Beth Høeg likely headed out at FDA: report
FierceBiotech Mar 31, 2026

Obesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic

Obesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic

Original
Body unavailable. Use the original source.